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Abstract
Inappropriate activation of c-mesenchymal-epithelial transition (MET), the receptor tyrosine kinase (RTK) for
hepatocyte growth factor (HGF), has been implicated in tumorigenesis and represented a promising therapeutic
target for developing anticancer agents. In contrast to other solid tumors, there are limited data describing the
functional role of HGF/c-MET signaling pathway in lymphoma. In the current review, we summarize recent findings
about the expression, cellular mechanisms/functions, and therapeutic application of HGF/c-MET in different types of
lymphoma, especially B cell lymphoma, T and NK cell lymphoma, and Hodgkin lymphoma. We also discuss the
existing problems and future directions about studying the HGF/c-MET pathway in lymphoma cells.
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Background
The mesenchymal-epithelial transition (MET) can be
utilized as a signaling receptor for hepatocyte growth
factor (HGF), and it has been reported that in
humans, the MET proto-oncogene encodes for the
receptor tyrosine kinase (RTK) of growth factor tyro-
sine kinase [1, 2]. The structure of MET protein
comprises a highly glycosylated 45-kDa extracellular
α-subunit and a 145-kDa transmembrane β-subunit,
which are linked together by a disulfide bridge
(Fig. 1). Upon binding to its ligand, HGF, two MET
subunits dimerize leading to auto-phosphorylation of
three tyrosine residues (Y1230, Y1234, Y1235) [3, 4].
This initial phosphorylation cascade is followed by
the phosphorylation of two other tyrosine residues
(Y1349, Y1356), and these residues have been shown
as docking sites for downstream signaling molecules
that mediate Ras/Raf/MAPK, PI3K/AKT/mTOR,
and/or STAT3/5 pathways [5–7]. HGF is known as a
paracrine cellular growth and a motility and mor-
phogenic factor. It is secreted by mesenchymal cells
and acts as a multi-functional cytokine on cells of
mainly epithelial origin after binding to the proto-
oncogenic c-MET receptor. In addition, an intricate
network of cross-signaling involving the c-MET-
epidermal growth factor receptor (EGFR), c-MET-
vascular endothelial growth factor receptor (VEGFR),
and c-MET-Wnt pathways has also been reported in
the past few years [8–10]. Such cross-talk implies/
elicits a variety of pleiotropic biological responses
leading to increased cell proliferation, survival, mi-
gration/invasion, angiogenesis, and metastasis in can-
cer cells [11]. HGF/c-MET has been extensively
studied as a therapeutic target in various cancers for
the last two decades, especially in lung cancer ther-
apy. For example, c-MET amplification or activation
has been reported as one of the major mechanisms
for developing resistance to EGFR tyrosine kinase in-
hibitor (TKI) treatment in non-small cell lung cancer
(NSCLC) patients [8, 12, 13]. However, few studies
about the role of HGF/c-MET signaling pathway in
lymphoma, a group of lymphocyte-derived cancers,
have been documented. Some of them showed the
conflicting results with favorable or unfavorable out-
come of HGF/c-MET, especially in diffuse large B
cell lymphoma (DLBCL). Based on the 2016 World
Health Organization (WHO) classification, the major
types of lymphoma include mature B cell lymphoma,
mature T and NK cell lymphoma, and Hodgkin
lymphoma, and each of them has many subtypes
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[14]. In the USA, lymphoma is the seventh most
common cancer with 19.5 and 2.6 of new cases and
6 and 0.4 of death cases per 100,000 persons per
year for non-Hodgkin and Hodgkin lymphoma, re-
spectively, from 2009 to 2013. In this review, we will
discuss the role of HGF/c-MET pathway in the
pathogenesis of lymphoma cells and potential therap-
ies for different types of lymphoma, based on recent
published data.
The expression/activation of HGF/c-MET in
different types of lymphoma and its outcome on
tumor progression
B cell-derived lymphoma
Weimar et al. reported that in several B cell-derived
lymphoma cell lines (BJAB, Raji, Ramos, Daudi, and
Jiyoye), two of them (BJAB, Raji) were c-MET positive
[15]. Within the same cell lineages, the presence of c-
MET could be variant, depending on the stages, specific
characteristics of cells in the development of these line-
ages, and the impact of cell-surrounding environment.
For example, c-MET is expressed on immature B cells,
e.g., CD19 + CD20− B cells, but not on mature CD19 +
CD20+ B cells. In addition, c-MET expression can be
upregulated by the activation of mature B cells with
CD40 ligand, phorbol 12-myristate 13-acetate (PMA), or
Epstein-Barr virus (EBV) infection. The role of HGF has
also been implicated in this B lymphoma. HGF induced
adhesion of c-MET-positive (but not of c-MET-negative)
B lymphoma cells to the extracellular matrix molecules,
fibronectin, and collagen [15]. HGF influenced the me-
tastasis of c-MET-positive cells into multiple organs, in-
cluding the liver, kidney, lymph nodes, lung, gonads, and
the central nervous system, in SCID mice but did not
affect metastasis of c-MET-negative lymphoma [15].
Since human B lymphoma cells can bind via their α4β1
integrin to murine VCAM-1 molecules [16, 17], HGF in-
duced adhesion of human c-MET-positive B cells to fi-
bronectin probably via the activation of α4β1 integrin
[15].
Diffuse large B cell lymphoma
In one of the most common B cell-derived lymph-
omas, DLBCL, c-MET was overexpressed in 26–73.2%
of cases and significantly associated with other signal-
ing molecules such as p-AKT, p-GSK3, and Ki-67 [18,
19]. Interestingly, the overexpression of c-MET in
DLBCL was associated with better survival in these
studies [18, 19]. This finding was unexpected and con-
flicting to the previous results with unfavorable out-
comes of HGF/c-MET signaling in lymphomas and
other cancers. One of the explanation is that c-MET-
positive lymphoma cells have retained the physio-
logical growth control by c-MET and possessed high
proliferative index, Ki67, resulting in cell cycle pro-
gression and possibly chemotherapy sensitivity [20].
However, in vitro c-MET tyrosine kinase activity could
activate AKT and its downstream substrates FOXO1 and
Fig. 1 The schematic diagram of HGF/c-MET signal transduction pathway
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GSK3 and induced anti-apoptosis [18]. Furthermore, it is
reinforced that after being surgically resected, primary
intestinal DLBCL with high c-MET copy numbers was as-
sociated with an unfavorable prognosis [19]. However,
even in one type of cancers, e.g., NSCLC, the impact of
c-METcopy number on prognosis is a histological subtype
dependent: c-MET amplification with a poorer prognosis
in patients with adenocarcinoma but not in those with
squamous cell carcinoma [21, 22]. More evidences have
been supporting the antiproliferative effect of HGF on
melanoma, hepatocellular carcinoma, breast cancer, and
leukemia, suggesting an antitumor effect for this growth
factor [1, 20, 23–25]. Contradictorily, high levels of serum
HGF and overactive HGF/c-MET pathway in DLBCL pa-
tients have been also reported to be linked with unfavor-
able outcome in several studies [26, 27]. HGF increased
the adhesion of c-MET-positive B cell lymphoma cells to
fibronectin and collagen, mediated via β1-integrin, and
furthermore, promoted migration and invasion. These
findings might indicate why HGF/c-MET-positive lym-
phomas have a poorer prognosis [27]. Interestingly, HGF
was localized in single and small cell clusters, activated
macrophages within the DLBCL tissues [28]. The lack of
HGF expression by some DLBCL cell lines indicates a
paracrine rather than an autocrine mechanism of c-MET
activation in DLBCL [28]. The other DLBCL cell lines
expressed HGF activator and are able to process HGF pre-
cursor to its active form [28]. HGF-induced activation of
c-MET in DLBCL cells resulted in MEK-dependent
phosphorylation of the MAP kinases ERK1 and ERK2, the
linkages to the regulation of cell proliferation [28]. HGF-
induced activation of c-MET induced PI3K-dependent
phosphorylation of PKB/AKT and its substrates GSK3 and
FOXO3a, contributing to its anti-apoptotic function [28].
Since HGF is an angiogenesis inducer [29] and has been
demonstrated to induce expression of vascular endothelial
growth factor (VEGF) as well [30, 31], it might also stimu-
late angiogenesis in DLBCL, thereby promoting tumor
growth. It is recently reported that fatty acid synthase
(FAS) inhibition triggered caspase-dependent apoptosis
and suppressed the expression of c-MET in DLBCL cell
lines [32]. Pharmacological FAS blockade might result in
rapid changes in the lipid composition of the tumor cell
membrane, which could impair a correct cellular
localization of c-MET [33]. Moreover, FAS inhibition may
cause an imbalance in the membrane phospholipids levels,
which may result in decreased c-MET membrane
localization and activation [34].
Primary effusion lymphoma
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the
etiologic agent of primary effusion lymphoma (PEL), which
comprises transformed B cells harboring the viral episome
and arises preferentially within the pleural or peritoneal
cavities of patients infected with HIV [35]. PEL is a rapidly
progressing malignancy with a median survival time of ap-
proximately 6 months even under the conventional chemo-
therapy [36]. Co-expression of HGF and c-MET was found
in all KSHV+ PEL cell lines [32, 37]. HGF stimulation of
PEL cells rapidly induces c-MET tyrosine phosphorylation
[30]. Our recent study found that KSHV de novo infection
greatly induced HGF production and the phosphorylation
of c-MET from primary endothelial cells [37]. In HIV-
infected patients, KSHV-positive group had higher plasma
HGF concentration than those from the KSHV-negative
group [37]. Blocking of HGF/c-MET pathway can induce
caspase-dependent PEL apoptosis through cell cycle arrest,
DNA damage, and suppression of downstream MAPK-ERK
activity [37]. Interestingly, it has been previously reported
that peritoneal fibroblasts produce significant amounts of
HGF [38]. Therefore, the activation of HGF/c-MET could
be involved in both an autocrine and a paracrine fashion in
PEL growth.
Burkitt’s lymphoma
Among Burkitt’s lymphoma cell lines, EB4 and Raji
expressed high levels of c-MET, while Namalwa cell line
was negative [39]. HGF protected EB4 and Raji lymphoma
cells from apoptosis induced by DNA damaging agents via
c-MET expression, which is potentially through the anti-
apoptotic mitochondrial pore-forming proteins Bcl-XL and
Bcl-2 [39]. The HGF/c-MET-mediated function or patho-
genesis can be reinforced in Namalwa cell line transfected
with c-MET [40]. CD44v3 splice variant promotes HGF-
induced phosphorylation of c-MET, phosphorylation of
several downstream proteins, and activation of the MAPK-
ERK1 [40]. This might be instrumental in promoting tumor
growth and metastasis, since ERK1/2 are intermediates in
signaling pathways linking extracellular signals to gene
transcription in the nucleus and have been implicated in a
wide variety of biological responses including cell prolifera-
tion [40].
Mucosa-associated lymphoid tissue lymphoma
c-MET was found in the lymphocytes composing mucosa-
associated lymphoid tissue (MALT) lymphoma, and HGF
was recognized mostly in the endothelial cells and macro-
phages in the MALT lymphoma [41]. HGF activator was
localized on the mesenchymal cells other than the lympho-
cytes. c-MET inhibition suppressed the hepatic and pul-
monary MALT lymphoma, while the gastric MALT
lymphoma showed only a tendency to decrease in size [41].
Hodgkin lymphoma
Hodgkin lymphoma is a B cell neoplasm characterized
by a minority of Reed-Sternberg (RS) cells in the infil-
trating reactive cells. In classical Hodgkin lymphoma
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(cHL) [30], the expression of c-MET was detected in the
tumor cells from 38 to 52% of the patients, and the ex-
pression of HGF was found in 8% of the patients [42,
43]. The c-MET expression is positive in L428, L1236,
and U-HO1 but negative in KMH2 cell lines. Expression
of c-MET in tumor cells from cHL patients strongly cor-
related with a favorable prognosis with a higher 5-year
survival rate compared with c-MET-negative tumor pa-
tients. It was explained that the percentage of cancer
cells in total cells of cHL is small, typically less than 1%,
whereas the percentage of cancer cells in DLBCL and
solid malignancies is generally between 40 and 80% [42].
In the infiltrating cells, several known effects of c-MET,
such as reducing organ fibrosis and upregulating pro-
inflammatory cytokines [44, 45], might explain the favor-
able effect of c-MET in cHL. In addition, c-MET could
reduce the TGF-β production, an immuno-suppressant,
and enhance the antitumor immunity [42, 43]. However,
it has confusedly been shown that high expression of c-
MET was associated with lower complete remission of
cHL in another study [46]. This conflicting could be due
to c-MET positivity limited to RS cells in the former
study, whereas c-MET in the latter one was inferred in
the whole cHL tissues. Another explanation is that it
was probably due to cross-talk between the malignant
cells and the reactive cells in the cHL tissue [46]. Inter-
estingly, RS cells expressed c-MET but not HGF and
several HGF-positive dendritic-reticulum cells were
found scattered around c-MET-positive RS cells [47].
This indicated that RS cells and the infiltrated reactive
cells in cHL were cross-talked via HGF/c-MET signaling
pathway.
T and NK cell-derived lymphoma
In anaplastic large cell lymphoma (ALCL), a type of T cell
lymphoma, c-MET is expressed in Karpas299 cells and
some other ALCL cell lines [48]. However, nucleophosmin-
anaplastic lymphoma kinase (ALK) but not c-MET has
been implicated in the pathogenesis of ALCL [48]. In
addition, HGF/c-MET were also expressed in natural killer/
T cell lymphoma (NKTCL) cell lines. NKTCL cells were
found to produce HGF and activate the HGF/c-MET sig-
naling pathway for the tumor cell proliferation in an auto-
crine manner [49]. The novel c-MET T helper (Th) cell
epitopes, c-MET278–292, 817–831, and 1244–1258, which
were restricted by HLA-DR molecules, HLA-DR9, HLA-
DR12, and HLA-DR53, respectively, have been identified
[49]. The c-MET-specific T helper (Th) cells could also
recognize dendritic cells (DCs) pulsed with c-MET
expressed tumor cell lysates. In addition, it has been ob-
served that c-MET inhibition augmented Th cell recogni-
tion by decreasing the TGF-β production by tumor cells.
Anti-autophagy is one of the protective mechanisms of
NKTCL because chaperon-dependent autophagy inhibitor,
17-DMAG, have been reported to suppress the cell growth
of NKTCL directly [50, 51]. Moreover, 17-DMAG signifi-
cantly reduced NKTCLTcell recognition [49].
In addition, the expression of c-MET was found in
PBMCs from adult T cell leukemia/lymphoma (ATLL)
patients and HTLV-1-infected T cell lines. HGF secreted
in paracrine rather than in autocrine mechanism seems
to be involved in the pathogenesis of ATLL [52]. ATLL
cells became more aggressive by the acquisition of c-
MET expression on its surface [52]. The proliferation of
primary cells in acute but not chronic ATLL cases was
induced by HGF [53]. Infiltrated ATLL cells and adja-
cent stromal cells in the liver of acute ATLL patients
have been shown to be positive for HGF/c-MET, sug-
gesting that the activation of HGF/c-MET was involved
in the aggression of ATLL cells [53]. Moreover, the activ-
ity of HGF/c-MET was enhanced by surrounding cyto-
kine environment. It was shown that ATLL cells as well
as HTLV-1-infected cells secreted not only IL-6 but
other HGF inducers such as IL-1ß and TNF-α, through
which the production of HGF in stromal cells could be
upregulated [54–56]. The functional role and underlying
mechanisms of HGF/c-MET pathway in different types
of lymphomas were listed in Table 1.
Targeting c-MET in lymphoma
Because of its pleiotropic role in oncogenesis and cancer
progression, HGF/c-MET is considered to be an import-
ant target in anticancer therapy. However, currently,
there are no HGF inhibitors that have been tried in
lymphoma treatment, so here, we will focus on c-MET
inhibitors, their application in lymphoma treatment
(Table 2). c-MET inhibitors are a class of small mole-
cules that inhibit the enzymatic activity of the c-MET
tyrosine kinase. PF-2341066, an ATP-competitive small-
molecule inhibitor of the catalytic activity of c-MET and
the ALK protein, was administered by oral gavage in
mice-bearing ALCL. PF-2341066 potently inhibited cell
proliferation, which was associated with G1 cell cycle ar-
rest and induction of apoptosis in ALK-positive ALCL
cells [48]. PF-2341066 was also administered intraperito-
neally in non-obese diabetic/severe-combined immuno-
deficiency (NOD/SCID) mice with KSHV-positive PEL
tumors. PF-2341066 treatment dramatically suppressed
PEL tumor progression including reducing ascites for-
mation and spleen enlargement over this time frame and
reduced expression of phosphor-c-MET and phosphor-
ERK within the spleen tissues [37]. As mentioned above,
PF-2341066 has been shown as the inhibitor to several
other RTKs such as ALK and ROS1 in different types of
cancer cells [48, 57]. Moreover, ALK inhibitors especially
second- and third-generation inhibitors have displayed
promising effects on ALK+ NSCLC patients even with
mutations [58–61]. However, PEL cell lines do not
Lam et al. Journal of Hematology & Oncology  (2016) 9:135 Page 4 of 8
express the p-ALK (Tyr1604), t-ALK, p-ROS1
(Tyr2274), or t-ROS1 reported in these previous studies
[37, 48, 57], implying that these virus-associated lymph-
oma cell lines may have unique expressional pattern of
RTKs.
SU11274, another ATP-competitive c-MET selective
inhibitor, blocked the constitutive phosphorylation of
c-MET and downstream kinases and induced G2/M cell
cycle arrest and significantly suppressed cell growth
in a dose-dependent manner [42]. Treatment with
PHA665752, a second generation of the highly selective c-
MET inhibitor, causes inactivation of c-MET, leading to
the inactivation of AKT and downstream signaling of
molecules FOXO1 and GSK3 in DLBCL cell lines.
PHA665752 treatment induced the activation of Caspase-
9, Caspase-3, and downstream PARP cleavage, the hall-
marks of cells undergoing apoptosis [18]. PHA-665752
was also injected intraperitoneally in mice with MALT
lymphoma, which induced the significant decrease in the
hepatic and pulmonary MALT lymphoma size and the
marked activation of Caspase 3 in fundic, hepatic, and
pulmonary MALT lymphoma [41]. NKTCL cell lines
treated with ARQ197, an ATP-non-competitive selective
c-MET inhibitor which is currently in phase 3 clinical tri-
als in NSCLC patients, reduced the proliferative response
by approximately 50% in two of three cell lines, indicating
that the HGF/c-MET signaling is partly responsible for
NKTCL proliferation [49].
Conclusions
There are only limited data studying the role of HGF/c-
MET signaling pathway in lymphomas, when compared
to those from other solid tumors. For example, MET
gene mutation and amplification represent one of the
major mechanisms causing constitutive active HGF/c-
MET signaling in cancer cells. However, no amplification
of the MET gene was found in B cell lymphoma cell lines
and patient samples [28]. Currently, only two germ line
missense mutations of c-MET have been found within B
cell lymphoma, especially DLBCL (R1166Q in the tyro-
sine kinase domain in one patient and R988C in the
Table 1 The impact of HGF/c-MET pathway in different types of lymphoma
Type of lymphoma Outcome Cellular functions, mechanisms, and clinical consequence References
B cell-derived Unfavorable Enhanced metastasis in vivo [15]
DLBCL Favorable ▪ Increase survival of patients
▪ c-MET retained the physiologic growth control
▪ c-MET(+) DLBCL was more proliferated and more
responsive to therapy
▪ c-MET directly binds to the pro-apoptotic protein FAS
[18, 23]
Primary intestinal DLBCL Unfavorable Reduce survival of patients [19]
DLBCL Unfavorable ▪ Increase the activities of MEK-MAPK
▪ Increase the activities of PI3K-PKB/AKT and
its substrates GSK3 and FOXO3a
▪ Inhibition of fatty acid synthase
[27, 28, 33]
PEL Unfavorable Required for tumor progression in xenograft model [37]
BL Unfavorable ▪ Protection of cells from apoptosis
▪ Activation of MAPK
▪ Induce drug resistance of tumor cells
[39, 40, 64]
MALT Unfavorable Required for tumor cell proliferation/growth [41]
cHL Favorable Increase survival of patients [42, 43]
cHL Unfavorable Increase the relapse [47]
ALCL Unfavorable Required for tumor progression [48]
NKTCL Unfavorable Required for tumor cell proliferation [49]
TLL Unfavorable Required for tumor progression [52, 53, 65]
Table 2 Targeting c-MET in lymphoma studies
Type of
lymphoma
c-MET inhibition Models/methods References
DLBCL PHA-665752 c-Met
siRNA
Cell lines in vitro
culture
[18]








cML SU11274 Cell lines in vitro
culture
[42]
ALCL PF-2341066 Mice xenograft
model
[48]
NKTCL ARQ197 c-MET mAb Cell lines in vitro
culture
[49]
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juxtamembrane domain in four patients) [28]. Therefore,
future work highlighting more potential mechanisms of
activating HGF/c-MET signaling from lymphoma cells
may uncover innovative therapeutic strategies for these
malignancies. To date, only a few c-MET inhibitors have
entered clinical trials, among which crizotinib and cabo-
zantinib were the first to be approved by the US FDA
for the treatment of certain solid tumor [62, 63]. How-
ever, none of them have been used in clinical trials for
any type of lymphoma. We should accelerate clinical
trial process by choosing those promising c-MET inhibi-
tors which have been shown to be dramatically effective
in lymphoma animal models.
Abbreviations
ALCL: Anaplastic large cell lymphoma; ALK: Anaplastic lymphoma kinase;
ATLL: Adult T cell leukemia/lymphoma; cHL: Classical Hodgkin lymphoma;
DCs: Dendritic cells; DLBCL: Diffuse large B cell lymphoma; EBV: Epstein-Barr
virus; EGFR: Epidermal growth factor receptor; FASN: Fatty acid synthase;
HGF: Hepatocyte growth factor; KSHV: Kaposi’s sarcoma-associated herpes-
virus; MALT: Mucosa-associated lymphoid tissue; MET: Mesenchymal-
epithelial transition; NKTCL: Natural killer/T cell lymphoma; NOD/SCID: Non-
obese diabetic/severe-combined immunodeficiency; NSCLC: Non-small cell
lung cancer; PEL: Primary effusion lymphoma; PMA: Phorbol 12-myristate 13-
acetate; RS cells: Reed-Sternberg cells; RTK: Receptor tyrosine kinase; Th cell: T
helper cell; TKI: Tyrosine kinase inhibitor; VEGFR: Vascular endothelial growth




This work was supported by grants from a DOD Career Development Award
to Z.Q. (CA140437), the SOM Research Enhancement Funding (2015–2016) to
Z.Q., the Leukemia Research Foundation (2016–2017) to Z.Q., and awards
from the National Natural Science Foundation of China (81272191, 81472547,
81672924 to Z.Q. and 81400164 to L.D.). Funding sources had no role in the
study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Availability of data and materials
The material supporting the conclusion of this review has been included
within the article.
Authors’ contributions
LBQ and ZQ drafted the manuscript. LD discussed and revised the
manuscript. All authors read and approved final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
This is not applicable for this review.
Ethics approval and consent to participate
This is not applicable for this review.
Received: 3 November 2016 Accepted: 1 December 2016
References
1. Shiota G, Rhoads DB, Wang TC, Nakamura T, Schmidt EV. Hepatocyte
growth factor inhibits growth of hepatocellular carcinoma cells. Proc Natl
Acad Sci U S A. 1992;89(1):373–7.
2. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G. Sequence
of MET protooncogene cDNA has features characteristic of the tyrosine
kinase family of growth-factor receptors. Proc Natl Acad Sci U S A.
1987;84(18):6379–83.
3. Ferracini R, Longati P, Naldini L, Vigna E, Comoglio PM. Identification of the
major autophosphorylation site of the Met/hepatocyte growth factor
receptor tyrosine kinase. J Biol Chem. 1991;266(29):19558–64.
4. Zhen Z, Giordano S, Longati P, Medico E, Campiglio M, Comoglio PM.
Structural and functional domains critical for constitutive activation of the
HGF-receptor (Met). Oncogene. 1994;9(6):1691–7.
5. Ponzetto C, Bardelli A, Maina F, Longati P, Panayotou G, Dhand R, Waterfield
MD, Comoglio PM. A novel recognition motif for phosphatidylinositol 3-
kinase binding mediates its association with the hepatocyte growth factor/
scatter factor receptor. Mol Cell Biol. 1993;13(8):4600–8.
6. Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W.
Interaction between Gab1 and the c-Met receptor tyrosine kinase is
responsible for epithelial morphogenesis. Nature. 1996;384(6605):173–6.
7. Zhu H, Naujokas MA, Fixman ED, Torossian K, Park M. Tyrosine 1356 in the
carboxyl-terminal tail of the HGF/SF receptor is essential for the
transduction of signals for cell motility and morphogenesis. J Biol Chem.
1994;269(47):29943–8.
8. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO,
Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads
to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science.
2007;316(5827):1039–43.
9. Sulpice E, Ding S, Muscatelli-Groux B, Berge M, Han ZC, Plouet J, Tobelem G,
Merkulova-Rainon T. Cross-talk between the VEGF-A and HGF signalling
pathways in endothelial cells. Biol Cell. 2009;101(9):525–39.
10. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH,
Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, et al. Wnt activity
defines colon cancer stem cells and is regulated by the microenvironment.
Nat Cell Biol. 2010;12(5):468–76.
11. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in
cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89–103.
12. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK,
Meyerson M, Eck MJ. The T790M mutation in EGFR kinase causes drug
resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A.
2008;105(6):2070–5.
13. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L,
Rogers A, Mok T, Sequist L, et al. Preexistence and clonal selection of MET
amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17(1):77–88.
14. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R,
Ghielmini M, Salles GA, Zelenetz AD, et al. The 2016 revision of the World
Health Organization classification of lymphoid neoplasms. Blood. 2016;
127(20):2375–90.
15. Weimar IS, Weijer K, van den Berk PC, Muller EJ, Miranda N, Bakker AQ,
Heemskerk MH, Hekman A, de Gast GC, Gerritsen WR. HGF/SF and its
receptor c-MET play a minor role in the dissemination of human B-
lymphoma cells in SCID mice. Br J Cancer. 1999;81(1):43–53.
16. Tsuzuki S, Toyama-Sorimachi N, Kitamura F, Tobita Y, Miyasaka M. FK506
(tacrolimus) inhibits extravasation of lymphoid cells by abrogating VLA-4/
VCAM-1 mediated transendothelial migration. FEBS Lett.
1998;430(3):414–8.
17. Renz ME, Chiu HH, Jones S, Fox J, Kim KJ, Presta LG, Fong S. Structural
requirements for adhesion of soluble recombinant murine vascular cell
adhesion molecule-1 to alpha 4 beta 1. J Cell Biol. 1994;125(6):1395–406.
18. Uddin S, Hussain AR, Ahmed M, Al-Dayel F, Bu R, Bavi P, Al-Kuraya KS.
Inhibition of c-MET is a potential therapeutic strategy for treatment of
diffuse large B-cell lymphoma. Lab Invest. 2010;90(9):1346–56.
19. Huang WT, Chuang SS. High MET gene copy number predicted poor prognosis
in primary intestinal diffuse large B-cell lymphoma. Diagn Pathol. 2013;8:16.
20. Ronen D, Altstock RT, Firon M, Mittelman L, Sobe T, Resau JH, Vande Woude
GF, Tsarfaty I. Met-HGF/SF mediates growth arrest and differentiation in
T47D breast cancer cells. Cell Growth Differ. 1999;10(2):131–40.
21. Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E,
Legrain M, Mennecier B, Wihlm JM, Massard G, et al. MET gene copy
number in non-small cell lung cancer: molecular analysis in a targeted
tyrosine kinase inhibitor naive cohort. J Thorac Oncol. 2008;3(4):331–9.
22. Shibata T, Uryu S, Kokubu A, Hosoda F, Ohki M, Sakiyama T, Matsuno Y,
Tsuchiya R, Kanai Y, Kondo T, et al. Genetic classification of lung
adenocarcinoma based on array-based comparative genomic hybridization
analysis: its association with clinicopathologic features. Clin Cancer Res.
2005;11(17):6177–85.
Lam et al. Journal of Hematology & Oncology  (2016) 9:135 Page 6 of 8
23. Koh YW, Hwang HS, Jung SJ, Park C, Yoon DH, Suh C, Huh J. Receptor
tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell
lymphoma patients receiving R-CHOP. Cancer Sci. 2013;104(9):1245–51.
24. Tajima H, Matsumoto K, Nakamura T. Hepatocyte growth factor has potent anti-
proliferative activity in various tumor cell lines. FEBS Lett. 1991;291(2):229–32.
25. Accordi B, Pillozzi S, Dell’Orto MC, Cazzaniga G, Arcangeli A, Kronnie GT, Basso
G. Hepatocyte growth factor receptor c-MET is associated with FAS and when
activated enhances drug-induced apoptosis in pediatric B acute lymphoblastic
leukemia with TEL-AML1 translocation. J Biol Chem. 2007;282(40):29384–93.
26. Hsiao LT, Lin JT, Yu IT, Chiou TJ, Liu JH, Yen CC, Wang WS, Chen PM. High
serum hepatocyte growth factor level in patients with non-Hodgkin’s
lymphoma. Eur J Haematol. 2003;70(5):282–9.
27. Kawano R, Ohshima K, Karube K, Yamaguchi T, Kohno S, Suzumiya J, Kikuchi
M, Tamura K. Prognostic significance of hepatocyte growth factor and c-
MET expression in patients with diffuse large B-cell lymphoma. Br J
Haematol. 2004;127(3):305–7.
28. Tjin EP, Groen RW, Vogelzang I, Derksen PW, Klok MD, Meijer HP, van Eeden
S, Pals ST, Spaargaren M. Functional analysis of HGF/MET signaling and
aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood.
2006;107(2):760–8.
29. Jiang W, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/
scatter factor, its molecular, cellular and clinical implications in cancer. Crit
Rev Oncol Hematol. 1999;29(3):209–48.
30. Wojta J, Kaun C, Breuss JM, Koshelnick Y, Beckmann R, Hattey E, Mildner M,
Weninger W, Nakamura T, Tschachler E, et al. Hepatocyte growth factor
increases expression of vascular endothelial growth factor and plasminogen
activator inhibitor-1 in human keratinocytes and the vascular endothelial
growth factor receptor flk-1 in human endothelial cells. Lab Invest.
1999;79(4):427–38.
31. Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, Schwall R, Ferrara N,
Gerritsen ME. Hepatocyte growth factor enhances vascular endothelial
growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol. 2001;
158(3):1111–20.
32. Capello D, Gaidano G, Gallicchio M, Gloghini A, Medico E, Vivenza D,
Buonaiuto D, Fassone L, Avanzi GC, Saglio G, et al. The tyrosine kinase
receptor met and its ligand HGF are co-expressed and functionally active in
HHV-8 positive primary effusion lymphoma. Leukemia. 2000;14(2):285–91.
33. Uddin S, Hussain AR, Ahmed M, Bu R, Ahmed SO, Ajarim D, Al-Dayel F, Bavi
P, Al-Kuraya KS. Inhibition of fatty acid synthase suppresses c-Met receptor
kinase and induces apoptosis in diffuse large B-cell lymphoma. Mol Cancer
Ther. 2010;9(5):1244–55.
34. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R.
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2)
oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A.
2004;101(29):10715–20.
35. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-
associated herpesvirus-like DNA sequences in AIDS-related body-cavity-
based lymphomas. N Engl J Med. 1995;332(18):1186–91.
36. Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma.
Oncologist. 2007;12(5):569–76.
37. Dai L, Trillo-Tinoco J, Cao Y, Bonstaff K, Doyle L, Del Valle L, Whitby D,
Parsons C, Reiss K, Zabaleta J, et al. Targeting HGF/c-MET induces cell cycle
arrest, DNA damage, and apoptosis for primary effusion lymphoma. Blood.
2015;126(26):2821–31.
38. Yashiro M, Chung YS, Inoue T, Nishimura S, Matsuoka T, Fujihara T, Sowa M.
Hepatocyte growth factor (HGF) produced by peritoneal fibroblasts may
affect mesothelial cell morphology and promote peritoneal dissemination.
Int J Cancer. 1996;67(2):289–93.
39. Skibinski G, Skibinska A, James K. Hepatocyte growth factor (HGF) protects
c-met-expressing Burkitt’s lymphoma cell lines from apoptotic death
induced by DNA damaging agents. Eur J Cancer. 2001;37(12):1562–9.
40. van der Voort R, Taher TE, Wielenga VJ, Spaargaren M, Prevo R, Smit L,
David G, Hartmann G, Gherardi E, Pals ST. Heparan sulfate-modified CD44
promotes hepatocyte growth factor/scatter factor-induced signal
transduction through the receptor tyrosine kinase c-Met. J Biol Chem. 1999;
274(10):6499–506.
41. Nakamura M, Takahashi T, Matsui H, Baniwa Y, Takahashi S, Murayama SY,
Serizawa H, Suzuki H, Hibi T. Alteration of angiogenesis in Helicobacter
heilmannii-induced mucosa-associated lymphoid tissue lymphoma:
interaction with c-Met and hepatocyte growth factor. J Gastroenterol
Hepatol. 2014;29 Suppl 4:70–6.
42. Xu C, Plattel W, van den Berg A, Ruther N, Huang X, Wang M, de Jong D,
Vos H, van Imhoff G, Viardot A, et al. Expression of the c-Met oncogene by
tumor cells predicts a favorable outcome in classical Hodgkin’s lymphoma.
Haematologica. 2012;97(4):572–8.
43. Wha Koh Y, Park C, Hyun Yoon D, Suh C, Huh J. MET and MST1R as prognostic
factors for classical Hodgkin’s lymphoma. Mod Pathol. 2013;26(9):1172–82.
44. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, Matsumoto K,
Nakamura T, Takahashi H, Okamoto E, et al. Hepatocyte growth factor gene
therapy of liver cirrhosis in rats. Nat Med. 1999;5(2):226–30.
45. Beilmann M, Vande Woude GF, Dienes HP, Schirmacher P. Hepatocyte growth
factor-stimulated invasiveness of monocytes. Blood. 2000;95(12):3964–9.
46. Bedewy M, El-Maghraby S, Bedewy A. CD163 and c-Met expression in the
lymph node and the correlations between elevated levels of serum free
light chain and the different clinicopathological parameters of advanced
classical Hodgkin’s lymphoma. Blood Res. 2013;48(2):121–7.
47. Teofili L, Di Febo AL, Pierconti F, Maggiano N, Bendandi M, Rutella S,
Cingolani A, Di Renzo N, Musto P, Pileri S, et al. Expression of the c-met
proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin
disease. Blood. 2001;97(4):1063–9.
48. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S,
Alton GR, Mroczkowski B, Los G. Cytoreductive antitumor activity of PF-
2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in
experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther.
2007;6(12 Pt 1):3314–22.
49. Kumai T, Matsuda Y, Ohkuri T, Oikawa K, Ishibashi K, Aoki N, Kimura S,
Harabuchi Y, Celis E, Kobayashi H. c-Met is a novel tumor associated antigen
for T-cell based immunotherapy against NK/T cell lymphoma.
Oncoimmunology. 2015;4(2):e976077.
50. Iwata S, Saito T, Ito Y, Kamakura M, Gotoh K, Kawada J, Nishiyama Y, Kimura
H. Antitumor activities of valproic acid on Epstein-Barr virus-associated T
and natural killer lymphoma cells. Cancer Sci. 2012;103(2):375–81.
51. Murata T, Iwata S, Siddiquey MN, Kanazawa T, Goshima F, Kawashima D,
Kimura H, Tsurumi T. Heat shock protein 90 inhibitors repress latent
membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr
virus-positive natural killer cell lymphoma. PLoS One.
2013;8(5):e63566.
52. Imaizumi Y, Murota H, Kanda S, Hishikawa Y, Koji T, Taguchi T, Tanaka Y,
Yamada Y, Ikeda S, Kohno T, et al. Expression of the c-Met proto-oncogene
and its possible involvement in liver invasion in adult T-cell leukemia. Clin
Cancer Res. 2003;9(1):181–7.
53. Onimaru Y, Tsukasaki K, Murata K, Imaizumi Y, Choi YL, Hasegawa H,
Sugahara K, Yamada Y, Hayashi T, Nakashima M, et al. Autocrine and/or
paracrine growth of aggressive ATLL cells caused by HGF and c-Met. Int J
Oncol. 2008;33(4):697–703.
54. Yamada Y, Ohmoto Y, Hata T, Yamamura M, Murata K, Tsukasaki K, Kohno T,
Chen Y, Kamihira S, Tomonaga M. Features of the cytokines secreted by
adult T cell leukemia (ATL) cells. Leuk Lymphoma. 1996;21(5–6):443–7.
55. Tendler CL, Greenberg SJ, Burton JD, Danielpour D, Kim SJ, Blattner WA,
Manns A, Waldmann TA. Cytokine induction in HTLV-I associated
myelopathy and adult T-cell leukemia: alternate molecular mechanisms
underlying retroviral pathogenesis. J Cell Biochem. 1991;46(4):302–11.
56. Yamano Y, Machigashira K, Ijichi S, Usuku K, Kawabata M, Arimura K, Osame
M. Alteration of cytokine levels by fosfomycin and prednisolone in
spontaneous proliferation of cultured lymphocytes from patients with HTLV-
I-associated myelopathy (HAM/TSP). J Neurol Sci.
1997;151(2):163–7.
57. Zou HY, Li Q, Engstrom LD, West M, Appleman V, Wong KA, McTigue M,
Deng YL, Liu W, Brooun A, et al. PF-06463922 is a potent and selective next-
generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1
mutations. Proc Natl Acad Sci U S A. 2015;112(11):3493–8.
58. Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, Liu D. Novel
ALK inhibitors in clinical use and development. J Hematol Oncol. 2015;8:17.
59. Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M
mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.
60. Wang S, Tsui ST, Liu C, Song Y, Liu D. EGFR C797S mutation mediates
resistance to third-generation inhibitors in T790M-positive non-small cell
lung cancer. J Hematol Oncol. 2016;9(1):59.
61. Wu J, Savooji J, Liu D. Second- and third-generation ALK inhibitors for non-
small cell lung cancer. J Hematol Oncol. 2016;9:19.
62. Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, Keegan P,
Pazdur R. FDA approval summary: crizotinib for the treatment of metastatic
Lam et al. Journal of Hematology & Oncology  (2016) 9:135 Page 7 of 8
non-small cell lung cancer with anaplastic lymphoma kinase
rearrangements. Oncologist. 2014;19(10):e5–11.
63. Ernani V, Kumar M, Chen AY, Owonikoko TK. Systemic treatment and
management approaches for medullary thyroid cancer. Cancer Treat Rev.
2016;50:89–98.
64. Jucker M, Gunther A, Gradl G, Fonatsch C, Krueger G, Diehl V, Tesch H. The
Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in
some cases of human leukemia and lymphoma. Leuk Res. 1994;18(1):7–16.
65. Accornero P, Lattanzio G, Mangano T, Chiarle R, Taulli R, Bersani F, Forni PE,
Miretti S, Scuoppo C, Dastru W, et al. An in vivo model of Met-driven
lymphoma as a tool to explore the therapeutic potential of Met inhibitors.
Clin Cancer Res. 2008;14(7):2220–6.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lam et al. Journal of Hematology & Oncology  (2016) 9:135 Page 8 of 8
